Altimmune Inc ALT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ALT is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $4.63
- Day Range
- $4.29–5.20
- 52-Week Range
- $2.09–16.76
- Bid/Ask
- $5.46 / $5.48
- Market Cap
- $277.78 Mil
- Volume/Avg
- 198,519 / 3.9 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 679.64
- Dividend Yield
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Altimmune Inc is engaged on developing treatments for obesity and liver diseases. The Company’s pipeline includes next generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (NASH) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). The Company is managed and operates as a single business focused on the research and development of treatments for various diseases and disorders, and vaccines.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 52
- Website
- https://www.altimmune.com
Valuation
|
Metric
|
ALT
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.82 |
Price/Sales | 679.64 |
Price/Cash Flow | — |
Price/Earnings
ALT
Financial Strength
|
Metric
|
ALT
|
|---|---|
Quick Ratio | 12.24 |
Current Ratio | 12.89 |
Interest Coverage | — |
Quick Ratio
ALT
Profitability
|
Metric
|
ALT
|
|---|---|
Return on Assets (Normalized) | −35.25% |
Return on Equity (Normalized) | −38.99% |
Return on Invested Capital (Normalized) | −42.74% |
Return on Assets
ALT
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Zrsx | $451.0 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Dftlr | $91.3 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Vqrbwd | $89.4 Bil | |
SGEN
| Seagen Inc Ordinary Shares | Xcxqn | $40.7 Bil | |
MRNA
| Moderna Inc | Hnkw | $29.8 Bil | |
ARGX
| argenx SE ADR | Qny | $27.8 Bil | |
BNTX
| BioNTech SE ADR | Ljjk | $23.5 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Svkrwv | $21.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Dsnsxj | $17.6 Bil | |
INCY
| Incyte Corp | Xhvtm | $12.3 Bil |